Drug distributors to pay up to $1.1 bln to settle New York opioid case

NEW YORK, July 20 (Reuters) – The three largest U.S. drug distributors agreed mid-trial to pay up to $1.1 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the state’s attorney general said on Tuesday.

McKesson Corp (MCK.N), Cardinal Health Inc (CAH.N) and AmerisourceBergen Corp (ABC.N) settled as state attorneys general prepare to announce as soon as this week a landmark $26 billion deal with the distributors and drugmaker Johnson & Johnson (JNJ.N) resolving cases nationwide. read more

The deal with New York Attorney General Letitia James and the populous Long Island counties of Nassau and Suffolk came three weeks into the first jury trial accusing companies of profiting from a flood of addictive painkillers that devastated communities. read more

Hunter Shkolnik, a lawyer for Nassau County at the law firm Napoli Shkolnik, in a statement said that unlike the proposed national settlement, the New York deal “is not contingent on the rest of the country or other states joining.”

“More importantly, it guarantees stringent injunctive relief that will help stop this from ever occurring again,” he said.

Nearly 500,000 people died from opioid overdoses in the United States from 1999 to 2019, according to the U.S. Centers for Disease Control and Prevention. And the crisis appeared to have worsened during the COVID-19 pandemic.

The CDC last week said provisional data showed that 2020 was a record year for drug overdose deaths with 93,331, up 29% from a year earlier. Opioids were involved in 74.7%, or 69,710, of those fatalities. read more

The New York trial will continue against three drugmakers accused of deceptively marketing their painkillers – Endo International Plc (ENDP.O), Teva Pharmaceutical Industries Ltd (TEVA.TA) and AbbVie Inc’s (ABBV.N) Allergan unit.

Reporting by Brendan Pierson in New York and Nate Raymond in Boston
Editing by Tom Hals, Chizu Nomiyama, Bill Berkrot and Nick Zieminski

Our Standards: The Thomson Reuters Trust Principles.

Source link

Related Articles

Stay Connected

21,935FansLike
3,912FollowersFollow
0SubscribersSubscribe

Latest Articles